Amplia Therapeutics Share Price and Company Fundamentals



Price
$0.25
Change
-0.005 (-1.961%)
52 week
0.074925 - 0.37

Last traded: Today at 12:46 AM

Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits (FAK). It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Key Metrics

PE ratio

-

PB ratio

2.23

Dividend yield

Beta

0.32

Market cap

$26.99M

Enterprise value

$23.63M

Company profile

Primary activitiesPharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.
Industry / SectorBiotechnology / Healthcare
Websitehttp://www.ampliatx.com
Mailing address90 Collins Street Level 21 Melbourne VIC 3000 Australia
Phone / Fax61 2 8003 3650 / 61 2 9225 5050
Share registryCOMPUTERSHARE INVESTOR SERVICES PTY LIMITED

Dividends

Amplia Therapeutics does not pay dividends.

Company Executives

As of May 2021, following are the company executives and directors listed on Amplia Therapeutics.

NameTitleAgeTotal Pay
Dr. John Lambert B.Sc., BSc (Hons), MRACI, C.Chem., Ph.D.CEO, MD & Director55174.13k
Mr. Jeff CarterChief Financial Officer6290.3k
Mr. Andrew John Cooke LLB, FAICS, MAICD, FGIA, FCISCompany Sec.6076.67k
Dr. Mark Devlin B.Sc., Ph.D.Chief Scientific Officer
Dr. Frank GelderFounding Scientist
Dr. James A. TaylorTrials Consultant59
Dr. Michael H. Silverman B.Sc., M.B.A., M.D., F.A.C.P., FACRTrials Consultant72
Dr. Benjamin M. SegalClinical Consultant
Dr. Frederick E. RenoToxicology Consultant

Profitability and management effectiveness

Profit margin

-206.39%

Operating margin

-212.99%

Return on assets

-10.91%

Return on equity

-17.59%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Amplia Therapeutics is 26.99M and its enterprise value is 23.63M. The enterprise value to revenue ratio of ATX is 26.43.

The ATX's stocks Beta value is 0.32 making it 68% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Amplia Therapeutics (ATX)

Amplia Therapeutics (ASX:ATX) Frequently Asked Questions

1. What is Amplia Therapeutics's Stock Symbol?

Amplia Therapeutics trades on ASX under the ticker symbol "ATX".

2. What is Amplia Therapeutics's stock price today?

One share of ATX stock can currently be purchased for approximately $0.25.

3. How can I contact Amplia Therapeutics?

Amplia Therapeutics's mailing address is 90 Collins Street Level 21 Melbourne VIC 3000 Australia. The company can be reached via phone at 61 2 8003 3650.

4. What is Amplia Therapeutics's official website?

The official website of Amplia Therapeutics is http://www.ampliatx.com.

5. Which share registry manages Amplia Therapeutics's stock?

Amplia Therapeutics's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.